Participants
Sixty-six anosmia related COVID -19 adult patients, 36 females and 30
males, were recruited during a period from August 2020 to January 2021
for this prospective trial study. Patients provided written informed
consent for their medical records before participating in this study.
Only patients over the age of 18 with history of confirmed COVID-19 and
olfactory dysfunction persisted more than 90 days after SARS-CoV-2
negative testing were included. Patients with neurodegenerative or other
conditions affecting olfaction were excluded. The patient
characteristics were recorded for each participant.